- Vedco, Inc. of St. Joseph, Missouri selected as U.S. distributor -
BELLEVILLE, ON, Nov. 21, 2012 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX:
BNC) (ASX: BNC), a research-based, technology-driven Canadian
biopharmaceutical company, today announced that it has appointed an
exclusive U.S. distributor for its ImmunocidinTM canine oncology therapy: St. Joseph, Missouri-based Vedco, Inc. ImmunocidinTM was launched at the annual U.S. Veterinary Cancer Society conference in
October of this year.
ImmunocidinTM is based on the Company's proprietary mycobacterial cell wall
technology, the same platform from which its Phase III product for
human bladder cancer (UrocidinTM) was derived. ImmunocidinTM is indicated as an immunotherapy for the intratumoral treatment of mixed
mammary tumor and mammary adenocarcinoma in dogs. The product has
received regulatory approval in Canada and the U.S. and is expected to
be launched in Canada in January, 2013.
Vedco will begin immediate distribution of ImmunocidinTM to veterinarians via its group of member distributors which includes
Butler Schein Animal Health, Merritt Veterinary Supply, Miller
Veterinary Supply, MWI Veterinary Supply, Penn Veterinary Supply and
Webster Veterinary Supply.
"We are pleased to have Vedco, Inc. as our U.S. distribution partner for
this product," said Mr. Andrew Grant, President, Bioniche Animal Health
(global). "Vedco is known for its broad and respected distribution
network, comprising more than 1,000 sales representatives throughout
Unlike commonly used canine oncology therapies, such as chemotherapy, ImmunocidinTM does not require special handling and can be used by veterinarians in
their own clinics, either alone or in combination with other therapies.
About Canine Cancer
Canine cancer is the leading disease-related cause of death in dogs,
with approximately one in four dying of cancer.
Where a treatment is used in dogs with cancer, it can involve surgery,
radiation therapy or chemotherapy. Radiation therapy is difficult to
access and chemotherapy is highly toxic, requiring handling by
specially trained personnel, which many companion animal veterinary
clinics do not have. These therapies have similar side effects in
animals as in humans (anorexia, nausea, hair loss, anemia, major
infections, etc.) and can vastly diminish the dog's quality of life.
Surgery and therapy costs for dogs with cancer can range from $3,000 to
$15,000 and above, depending upon type and stage of cancer, number and
type of primary and supportive treatments required, the age and
condition of the dog, and the location of treatment (travel costs).
About Bioniche Life Sciences Inc.
Bioniche Life Sciences Inc. is a research-based, technology-driven
Canadian biopharmaceutical company focused on the discovery,
development, manufacturing, and marketing of proprietary and innovative
products for human and animal health markets worldwide. The
fully-integrated company employs more than 200 skilled personnel and
has three operating divisions: Human Health, Animal Health, and Food
Safety. The Company's primary goal is to develop and commercialize
products that advance human or animal health and increase shareholder
Bioniche Animal Health develops, manufactures and markets veterinary
biopharmaceutical products worldwide. In North America, it has
development, manufacturing and marketing facilities in Belleville,
Ontario, Canada, Athens, Georgia, U.S.A. and Pullman, Washington,
U.S.A. In Australia, business is conducted from two sites: Sydney, New
South Wales, where sales and marketing, customer support and technical
service are located; and Armidale, New South Wales, where research,
development and manufacturing facilities are located.
For more information, please visit www.Bioniche.com.
Except for historical information, this news release may contain
forward-looking statements that reflect the Company's current
expectation regarding future events. These forward-looking statements
involve risk and uncertainties, which may cause, but are not limited
to, changing market conditions, the successful and timely completion of
clinical studies, the establishment of corporate alliances, the impact
of competitive products and pricing, new product development,
uncertainties related to the regulatory approval process, and other
risks detailed from time to time in the Company's ongoing quarterly and
SOURCE Bioniche Life Sciences Inc.